# TAPT1 siRNA (h): sc-89016



The Power to Question

#### **BACKGROUND**

TAPT1 (transmembrane anterior posterior transformation protein 1 homolog), also known as cytomegalovirus partial fusion receptor (CMVFR), is a 567 amino acid multi-pass membrane protein belonging to the TAPT1 family. TAPT1 is ubiquitously expressed and highly conserved, and may function as a transmitter of extracellular information required for axial skeletal patterning during development. TAPT1 exists as two alternatively spliced isoforms, and is encoded by a gene that maps to human chromosome 4p15.32. Chromosome 4 represents approximately 6% of the human genome and contains nearly 900 genes. The Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is located on chromosome 4. FGFR-3 is also encoded by a gene that maps to human chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease.

## **REFERENCES**

- Bonaventure, J., et al. 1996. Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Am. J. Med. Genet. 63: 148-154.
- Kalchman, M.A., et al. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271: 19385-19394.
- Singhrao, S.K., et al. 1998. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp. Neurol. 150: 213-222.
- Krakow, D., et al. 2000. Exclusion of the Ellis-van Creveld region on chromosome 4p16 in some families with asphyxiating thoracic dystrophy and short-rib polydactyly syndromes. Eur. J. Hum. Genet. 8: 645-648.
- Sommardahl, C., et al. 2001. Phenotypic variations of orpk mutation and chromosomal localization of modifiers influencing kidney phenotype. Physiol. Genomics 7: 127-134.
- Utine, G.E. and Aktas, D. 2006. Mosaicism for terminal deletion of 4q. Genet. Couns. 17: 205-209.
- 7. Howell, G.R., et al. 2007. Mutation of a ubiquitously expressed mouse transmembrane protein (Tapt1) causes specific skeletal homeotic transformations. Genetics 175: 699-707.
- Ching, Y.H., et al. 2010. High resolution mapping and positional cloning of ENU-induced mutations in the Rw region of mouse chromosome 5. BMC Genet. 11: 106.
- Kalsi, G., et al. 2010. A systematic gene-based screen of chr4q22-q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts. Hum. Mol. Genet. 19: 2497-2506.

#### **CHROMOSOMAL LOCATION**

Genetic locus: TAPT1 (human) mapping to 4p15.32.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PRODUCT**

TAPT1 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see TAPT1 shRNA Plasmid (h): sc-89016-SH and TAPT1 shRNA (h) Lentiviral Particles: sc-89016-V as alternate gene silencing products.

For independent verification of TAPT1 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-89016A, sc-89016B and sc-89016C.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### **APPLICATIONS**

TAPT1 siRNA (h) is recommended for the inhibition of TAPT1 expression in human cells.

# **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

### **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor TAPT1 gene expression knockdown using RT-PCR Primer: TAPT1 (h)-PR: sc-89016-PR (20  $\mu$ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

### **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.